辉瑞制药高级副总裁钱云建议，广东可借助先发优势，率先建设"省级商保创新药结算平台"，彻底告 别"先垫付、后理赔"，同时统一标准以降低保险公司运营成本，形成"目录—支付—使用"的良性循环。 强生创新制药中国区总裁黄琛则建议出台具体激励措施，鼓励医疗机构加快落地商保，并加强国谈药落 地政策的培训宣传，让好政策真正穿透至医生层面。 1月28日，2026跨国药企大湾区行座谈会在广州举行。来自强生、辉瑞、阿斯利康、拜耳等15家跨国药 企的40余位中国区总裁及部门负责人，广东省有关单位和珠三角九市政府相关负责人和专家齐聚一堂， 一场汇聚全球医药产业顶尖智慧的对话在此展开。 各方围绕"国家医保谈判药物在大湾区落地""创新药商业健康保险进展""'港澳药械通'实施与优化"等话 题进行深入交流，展现大湾区吸引全球医药创新资源的决心，勾勒出构建开放共赢产业生态的路径。 政企共探医药高质量发展"湾区方案" 座谈会上，广东省相关部门负责人介绍，近两年来，广东密集出台了近20份相关政策文件，形成覆盖全 产业链的发展规划、针对优势领域的专项政策及布局未来产业的行动方案"组合拳"，旨在为企业打造全 方位、可持续的优良发展环境。 与会跨国药企 ...

Core Insights - The gathering of over 40 executives from 15 multinational pharmaceutical companies in the Greater Bay Area (GBA) highlights the region's growing importance in the biopharmaceutical industry [1][3] - The event serves as a platform for dialogue between government and industry leaders to explore the GBA's advantages and future potential in biopharmaceutical development [1][3] Group 1: Investment and Development - Multinational pharmaceutical companies are increasingly establishing production bases and regional headquarters in the GBA, signaling strong confidence in the region's biopharmaceutical industry [3][4] - The GBA has been recognized for its favorable business environment, with Guangdong province leading in foreign investment and being rated as having the best business environment in China [4][6] Group 2: Market Potential and Resources - Guangdong's healthcare market is vast, with a basic medical insurance enrollment of 112 million people by the end of 2024, and it leads the nation in the scale of pharmaceutical circulation and the number of top-tier hospitals [4][9] - The integration of the Guangdong-Hong Kong-Macao markets is unlocking significant potential in the biopharmaceutical sector, with a focus on translating advantages into patient benefits [6][12] Group 3: Regulatory and Collaborative Framework - The "Hong Kong-Macao Drug and Medical Device Access" initiative has facilitated the approval of 149 drug and medical device varieties, enhancing patient access to innovative treatments [7][8] - The establishment of a provincial commercial health insurance platform aims to alleviate patient financial burdens, further promoting the use of innovative drugs [8][9] Group 4: Innovation and Research - The GBA is becoming a key innovation hub, with one-third of global biopharmaceutical research pipelines originating from China, and many multinational companies are shifting early-stage research to the region [9][11] - The region has seen a significant increase in the approval of innovative drugs and medical devices, with a 667% increase in first-class innovative drugs approved during the 14th Five-Year Plan compared to the previous period [9][10] Group 5: Future Directions and Challenges - The collaboration between Guangdong and Hong Kong is crucial for enhancing the accessibility of innovative drugs, with a focus on real-world data and joint research initiatives [12][16] - Challenges such as cross-border regulation, data flow, and talent mobility need to be addressed to optimize the biopharmaceutical industry's collaborative efforts in the GBA [16][17]

Group 1 - Bayer's oral contraceptive Youshuai® 84-pack has successfully completed import clearance and is launched on Alibaba Health, aiming to enhance medication convenience and adherence for women's long-term health management [1] - The "Consensus on Clinical Application of Combined Oral Contraceptives in China" has been initiated, focusing on improving women's awareness of the importance of medication adherence in disease management [3] - The low usage rate of combined oral contraceptives (COC) among women of childbearing age in China is attributed to fear of hormonal drugs and insufficient understanding, leading to missed opportunities for effective health benefits [3] Group 2 - Youshuai® is a short-acting oral contraceptive approved in China since December 2014, featuring a "24+4" dosing regimen, suitable for contraception and treatment of moderate acne in females aged 14 and above [3] - The launch of Youshuai® 84-pack is expected to reduce the frequency of medication purchases and improper discontinuation, thereby enhancing patient adherence and continuity of treatment [3] - Alibaba Health provides a comprehensive online healthcare service system, ensuring convenient access to medications and maintaining treatment continuity through efficient nationwide delivery [4]

Core Insights - Bayer's oral contraceptive Youshu Yue in a 84-tablet pack has successfully completed import customs clearance and is launched on Alibaba Health, aiming to enhance medication convenience and adherence for women's health management [1][3] - The launch coincides with the initiation of the "Consensus on Clinical Application of Combined Oral Contraceptives in China," which emphasizes the importance of medication adherence in disease management for women [3] Group 1: Product Launch and Features - Youshu Yue is designed to cover a complete three-month medication cycle, addressing the actual needs of long-term health management for women [1] - The product is a short-acting oral contraceptive approved in China since December 2014, featuring a "24+4" dosing regimen, which includes 24 active tablets and 4 inactive tablets [3] - It is indicated for contraception and treatment of moderate acne in females aged 14 and above without known contraindications for oral contraceptives [3] Group 2: Market Context and Challenges - The usage rate of combined oral contraceptives (COCs) among women of childbearing age in China is notably low, primarily due to fears of hormonal medications and insufficient understanding of COCs [3] - The lack of awareness leads to underutilization of COCs, which can provide both contraceptive and non-contraceptive health benefits [3] Group 3: Service and Distribution - Alibaba Health serves as a platform for the launch, providing a comprehensive online healthcare service system, including professional pharmacist reviews and medication guidance [4] - The platform addresses the inconvenience of purchasing medications due to time and geographical limitations, ensuring continuity of treatment through efficient nationwide delivery [4]

本报讯 （记者袁传玺）1月29日，拜耳原研口服避孕药优思悦®84片装大包装首批药品顺利完成进口通关，率先在阿里健 康首发，该规格于第八届中国国际进口博览会首次亮相，旨在覆盖三个月完整的用药周期，提升用药的便利性和依从性，更好 地契合女性健康长周期管理的实际需求。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的慢性病患者，经专业医 生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦因购药不及时而中断，往往会影响疗效。优思 悦®84片装的推出，有助于减少频繁购药和不当停药的情况，提升患者依从性和用药连续性，为临床实践和患者管理提供了更 为便利的选择。" 优思悦®（屈螺酮炔雌醇片Ⅱ）是一种短效口服避孕药，2014年12月份在中国获批上市，是中国首个采用"24+4"给药模式 的复方口服避孕药，24片活性药片（每片含0.02mg炔雌醇和3mg屈螺酮）加4片无活性药片，适用于女性避孕，及≥14岁、没有 口服避孕药已知禁忌的已初潮女性的中度寻常痤疮治疗，只有在患者希望使用口服避孕药作为避孕措施时才能使用本品治疗痤 疮。优思悦®通过调节激素水平辅助治疗痤疮，通常至少 ...

Group 1: Lier Chemical - Lier Chemical is a global leader in chlorinated pyridine herbicides and a leading company in glyphosate and refined glyphosate, with products sold in over 30 countries and regions [1] - The core growth logic is driven by the accelerated ban on glyphosate, with the market size for glyphosate expected to grow from 3 billion yuan in 2020 to 8 billion yuan in 2025, representing a compound annual growth rate (CAGR) of 22% [1] - Lier Chemical is the second company globally and the first in China to master the industrialization of cyanopyridine chlorination technology, with a total production capacity exceeding 50,000 tons per year, achieving full production and sales [1] - The company has a market share of over 70% globally, with more than 80% of its sales coming from long-term supply agreements, and both product categories are currently in a price increase cycle [1] - The company has seen its performance improve by over 100% for three consecutive quarters [1] Group 2: Shandong Heda - Shandong Heda is the absolute leader in cellulose ether in China and a core supplier of plant capsules globally, with raw materials sourced from cotton, wood, and bamboo [2] - The focus is on medical-grade and food-grade cellulose ether, with profit margins reaching 25% to over 35%, particularly for medical-grade cellulose ether, which sees annual price increases and growing margins [2] - The company has established long-term supply agreements with major domestic pharmaceutical companies such as Heng Rui and Shi Yao, as well as international firms like Pfizer, Novartis, and Bayer, supplying 15 out of the top 20 global pharmaceutical companies [2] - The global capsule market is over 30 billion yuan, with the share of plant capsules expected to increase from 15% in 2020 to 30% in 2025, reflecting a CAGR of over 20% as a clear trend to replace gelatin capsules [2] - Shandong Heda has a domestic production capacity of 20 billion capsules per year, with a $500 million investment in the U.S. to build a project with the same capacity, expected to be operational by Q3 2026 [2]

硅谷大厂HR标配的AI招聘系统，搞得天怒人怨。 微软、拜耳、PayPal都在用的AI招聘Eightfold AI，被两名求职者告上了法庭。 这家主打"用AI帮企业更高效选人"的公司，被指控其算法在实际招聘过程中造成了歧视。 除了经济赔偿外，这俩打工人还喊话法院，必须管管黑箱算法，提高招聘筛选过程的透明度。 这事儿在持续发酵的同时，另一个离谱的研究也冒了出来—— AI居然能根据一张人脸照片，预测你的职业走向…… 何意味？赛博相面？ AI怎么就成了"面相大师" 虽然听上去像AI算命2.0，但这项研究竟然是由多所美国顶级高校的研究者完成的。 从学术角度来看，它用的数据规模和研究方法还挺扎实。 研究团队收集了近10万名MBA毕业生的数据，涵盖美国排名前110的商学院； 这些数据包括教育背景和完整的职业轨迹，还有领英人脸头像以及院校相册里的照片。 研究的核心做法是先用1.2万多人的自拍+性格问卷训练AI，让它能把人脸转换成数字信号，并据此预测个体的五大人格特质。 五大人格是心理学界公认的性格测评标准，包括外向性、尽责性、开放性、宜人性（好相处）和神经质。 随后，他们将这些由AI预测出的人格特征，与现实世界中的结果进行对 ...

闻乐 发自 凹非寺 量子位 | 公众号 QbitAI 硅谷大厂HR标配的AI招聘系统，搞得天怒人怨。 微软、拜耳、PayPal都在用的AI招聘 Eightfold AI ，被两名求职者告上了法庭。 这家主打"用AI帮企业更高效选人"的公司，被指控其算法在实际招聘过程中造成了歧视。 除了经济赔偿外，这俩打工人还喊话法院，必须管管黑箱算法， 提高招聘筛选过程的透明度 。 这事儿在持续发酵的同时，另一个离谱的研究也冒了出来—— AI居然能根据一张人脸照片，预测你的职业走向…… 何意味？赛博相面？ AI怎么就成了"面相大师" 虽然听上去像AI算命2.0，但这项研究竟然是由多所美国顶级高校的研究者完成的。 从学术角度来看，它用的数据规模和研究方法还挺扎实。 研究团队收集了近10万名MBA毕业生的数据，涵盖美国排名前110的商学院； 这些数据包括教育背景和完整的职业轨迹，还有领英人脸头像以及院校相册里的照片。 研究的核心做法是先用1.2万多人的自拍+性格问卷训练AI，让它能把人脸转换成数字信号，并据此预测个体的五大人格特质。 五大人格是心理学界公认的性格测评标准，包括外向性、尽责性、开放性、宜人性（好相处）和神经质。 随 ...

Core Insights - Johnson & Johnson (JNJ) reported fourth-quarter 2025 earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.43, with a year-over-year increase of 20.6% [1] - Total sales reached $24.56 billion, surpassing the Zacks Consensus Estimate of $24.12 billion [1] Sales Performance - Overall sales increased by 9.1% compared to the previous year, driven by a 7.1% operational increase and a 2.0% positive currency impact [2] - Domestic sales rose 7.5% to $14.2 billion, with an adjusted operational increase of 5.7% [2] - International sales grew by 11.3% to $10.4 billion, reflecting a 6.6% operational increase and a 4.7% positive currency impact [3] Segment Performance - The Innovative Medicines segment saw a 10.0% year-over-year sales increase to $15.76 billion, beating the Zacks Consensus Estimate of $15.43 billion [4] - Key products such as Darzalex, Tremfya, and Erleada contributed significantly to the segment's growth, while new drugs like Carvykti and Tecvayli also played a role [5][6] Oncology Drug Performance - Darzalex sales rose 26.6% to $3.9 billion, exceeding the Zacks Consensus Estimate of $3.74 billion [6] - Erleada generated $959 million in sales, up 22.4% year over year, beating the Zacks Consensus Estimate of $936 million [7] - Imbruvica sales declined 6.5% to $684 million due to competitive pressures, although it was better than the Zacks Consensus Estimate of $670 million [6] Immunology Drug Performance - Stelara sales fell 47.7% to $1.23 billion due to biosimilar competition, missing the Zacks Consensus Estimate of $1.36 billion [10] - Tremfya recorded sales of $1.59 billion, up 67.6% year over year, surpassing the Zacks Consensus Estimate of $1.36 billion [11] MedTech Segment Performance - MedTech segment sales reached $8.8 billion, up 7.5% from the previous year, beating the Zacks Consensus Estimate of $8.71 billion [15] - The growth was driven by strong performance in Cardiovascular, Surgery, and Vision segments [15] Full-Year Results and Guidance - For the full year 2025, sales rose 6.0% to $94.2 billion, exceeding the Zacks Consensus Estimate of $93.73 billion [17] - JNJ expects 2026 sales in the range of $100 billion to $101 billion, indicating growth of 6.2%-7.2% [19] - Adjusted earnings per share for 2026 are projected to be between $11.43 and $11.63, with the Zacks Consensus Estimate at $11.46 [20] Market Reaction - Despite strong quarterly results and positive guidance for 2026, JNJ shares fell approximately 3% in pre-market trading, likely due to concerns over Stelara's sales decline and broader economic issues [23]

Company Overview - Arcellx, Inc. (ACLX) is part of the Medical group, which consists of 932 companies and currently ranks 8 within the Zacks Sector Rank [2] - The company belongs to the Medical - Biomedical and Genetics industry, which includes 453 companies and is ranked 93 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcellx, Inc. has returned approximately 10.7%, outperforming the average gain of 6% for Medical stocks [4] - The Zacks Consensus Estimate for ACLX's full-year earnings has increased by 1.2% over the past quarter, indicating improved analyst sentiment [4] Comparison with Peers - Bayer Aktiengesellschaft (BAYRY), another Medical stock, has outperformed the sector with a year-to-date return of 15.6% and a Zacks Rank of 1 (Strong Buy) [5] - The Large Cap Pharmaceuticals industry, which includes Bayer, has gained 19.8% since the beginning of the year, while Arcellx, Inc. is slightly underperforming its industry group [6][7]